{
  "literature_update_interval": 7,
  "confidence_threshold": 0.6,
  "max_contradictions": 2,
  "priority_weights": {
    "therapeutic_impact": 0.4,
    "feasibility": 0.3,
    "cost": 0.2,
    "timeline": 0.1
  },
  "literature_sources": {
    "pubmed_api": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/",
    "arxiv_api": "http://export.arxiv.org/api/query",
    "search_terms": [
      "cannabidiol glioma",
      "CBD mitochondria",
      "VDAC1 cannabinoid",
      "TRPV4 biomarker",
      "ROS selectivity",
      "chloride channels CBD"
    ]
  },
  "experimental_protocols": {
    "binding_assay": {
      "equipment": ["SPR_system", "spectrophotometer"],
      "reagents": ["CBD_pure", "VDAC1_recombinant", "binding_buffer"],
      "controls": ["vehicle", "positive_control", "negative_control"]
    },
    "cell_viability": {
      "cell_lines": ["U87MG", "T98G", "normal_astrocytes"],
      "assays": ["MTT", "LDH", "annexin_V"],
      "timepoints": [24, 48, 72]
    }
  },
  "clinical_development": {
    "regulatory_requirements": {
      "preclinical": ["GLP_toxicity", "pharmacokinetics", "formulation"],
      "phase_1": ["safety_profile", "dose_escalation", "biomarker_validation"],
      "phase_2": ["efficacy_endpoints", "optimal_dosing", "patient_stratification"]
    },
    "go_no_go_criteria": {
      "discovery_to_preclinical": {
        "binding_validated": true,
        "selectivity_index": "> 2.0",
        "mechanism_confidence": "> 0.7"
      },
      "preclinical_to_clinical": {
        "safety_margin": "> 10x",
        "biomarker_validated": true,
        "formulation_stable": true,
        "regulatory_approval": "IND_ready"
      }
    }
  },
  "risk_management": {
    "literature_contradictions": {
      "threshold": 2,
      "action": "expert_review"
    },
    "confidence_degradation": {
      "threshold": 0.1,
      "timeframe": 30,
      "action": "re_validation"
    },
    "paradigm_shifts": {
      "keywords": ["mechanism", "paradigm", "challenges", "contradicts"],
      "action": "immediate_review"
    }
  },
  "resource_allocation": {
    "budget_priorities": {
      "binding_studies": 0.3,
      "selectivity_validation": 0.25,
      "biomarker_development": 0.2,
      "mechanism_studies": 0.15,
      "formulation": 0.1
    },
    "timeline_constraints": {
      "discovery_phase": 180,
      "preclinical_phase": 365,
      "regulatory_prep": 90
    }
  }
}